Education
About Us
Working with TipRanks
Follow Us
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
ALLR Stock Chart & Stats
$1.14
-$0.01(-0.99%)
At close: 4:00 PM EST
$1.14
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$0.61 - $2.35
Previous CloseN/A
Volume542.33K
Average Volume (3M)146.33K
Market Cap
$18.79M
Enterprise Value$7.78M
Total Cash (Recent Filing)$16.89M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding16,057,200
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$9.50Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$99.78M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive clinical trials data in 2025/26 are expected to be strong catalysts for the stock.
Drug DevelopmentStenoparib has shown promising, durable clinical benefits in patients with limited treatment options.
Market PotentialThe large market potential for ovarian cancer and the growing market for PARP inhibitors present significant opportunities for Allarity Therapeutics.
Bears Say
Development ChallengesAllarity Therapeutics faces high risks due to long development challenges and potential for commercialization failures.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.61 and its highest was $2.35 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $18.79M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is May 18, 2026 which is in 124 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.04.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 16,057,200 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went down -0.84%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$9.50
▲(733.33% Upside)
Technical Analysis
Ownership Overview
4.71%
Insiders
1.67% Mutual Funds
<0.01% Other Institutional Investors
92.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---